Literature DB >> 15832502

A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists.

Teresa N Faria1, Julita K Timoszyk, Terry R Stouch, Balvinder S Vig, Christopher P Landowski, Gordon L Amidon, C David Weaver, Doris A Wall, Ronald L Smith.   

Abstract

PepT1 is a transporter of proven pharmaceutical utility for enhancing oral absorption. A high-throughput, robust functional assay, capable of distinguishing PepT1 binders from substrates, allowing identification and/or prediction of drug candidate activation was developed. An MDCK epithelial cell line was transfected with rPepT1. The high level of stable rPepT1 expression that was achieved enabled development of a miniaturized PepT1 assay in a 96-well format, which could be scaled to 384 wells. The assay is based on measurement of membrane depolarization resulting from the cotransport of protons and PepT1 substrates. Membrane potential changes are tracked with a voltage-sensitive fluorescent indicator. Control (mock-transfected) cells are used to determine nonspecific membrane potential changes. A variety of fluorescent dyes were tested during initial assay design, including intracellular pH and membrane potential indicators. A membrane potential indicator was chosen because of its superior performance. Upon PepT1 activation with glycylsarcosine, dose-dependent membrane depolarization was observed with an EC50 of 0.49 mM. Maximum depolarization was dependent on the level of PepT1 expression. Testing of 38 known PepT1 substrates, binders, and nonbinders demonstrated that this assay accurately distinguished substrates from binders and from nonbinders. Initial validation of this novel assay indicates that it is sensitive and robust, and can distinguish between transporter substrates and antagonists. This important distinction has been previously achieved only with lower-throughput assays. This assay might also be used to determine substrate potency and establish a high-quality data set for PepT1 SAR modeling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15832502     DOI: 10.1021/mp034001k

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  13 in total

1.  Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen.

Authors:  Diana Højmark Omkvist; Birger Brodin; Carsten Uhd Nielsen
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 2.  Strategic approaches to optimizing peptide ADME properties.

Authors:  Li Di
Journal:  AAPS J       Date:  2014-11-04       Impact factor: 4.009

Review 3.  Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease.

Authors:  Emilie Viennois; Adani Pujada; Jane Zen; Didier Merlin
Journal:  Compr Physiol       Date:  2018-03-25       Impact factor: 9.090

4.  Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.

Authors:  Christopher P Landowski; Xueqin Song; Philip L Lorenzi; John M Hilfinger; Gordon L Amidon
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

5.  In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients.

Authors:  Katja Berginc; Simon Žakelj; Albin Kristl
Journal:  Eur J Nutr       Date:  2010-02-07       Impact factor: 5.614

6.  Substrate specificity and mechanism of the intestinal clonidine uptake by Caco-2 cells.

Authors:  Wiebke Fischer; Linda Metzner; Kathrin Hoffmann; Reinhard H H Neubert; Matthias Brandsch
Journal:  Pharm Res       Date:  2006-12-13       Impact factor: 4.200

7.  Structural basis for dynamic mechanism of proton-coupled symport by the peptide transporter POT.

Authors:  Shintaro Doki; Hideaki E Kato; Nicolae Solcan; Masayo Iwaki; Michio Koyama; Motoyuki Hattori; Norihiko Iwase; Tomoya Tsukazaki; Yuji Sugita; Hideki Kandori; Simon Newstead; Ryuichiro Ishitani; Osamu Nureki
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

8.  Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.

Authors:  Sheeba Varghese Gupta; Deepak Gupta; Jing Sun; Arik Dahan; Yasuhiro Tsume; John Hilfinger; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2011-09-22       Impact factor: 4.939

9.  Functional implications and ubiquitin-dependent degradation of the peptide transporter Ptr2 in Saccharomyces cerevisiae.

Authors:  Ken Kawai; Atsuto Moriya; Satoshi Uemura; Fumiyoshi Abe
Journal:  Eukaryot Cell       Date:  2014-08-29

10.  Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies.

Authors:  Agnès Poirier; Sara Belli; Christoph Funk; Michael B Otteneder; Renée Portmann; Katja Heinig; Eric Prinssen; Stanley E Lazic; Craig R Rayner; Gerhard Hoffmann; Thomas Singer; David E Smith; Franz Schuler
Journal:  Drug Metab Dispos       Date:  2012-05-14       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.